The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year
Kuo-Chen Cheng,Chih-Cheng Lai,Cheng-Yi Wang,Ching-Min Wang,Chung-Han Ho,Mei-I Sung,Shu-Chen Hsing,Kuang-Ming Liao,Shian-Chin Ko
DOI: https://doi.org/10.2147/COPD.S349468
2022-04-22
International Journal of COPD
Abstract:Kuo-Chen Cheng, 1, &ast Chih-Cheng Lai, 2, &ast Cheng-Yi Wang, 3 Ching-Min Wang, 4 Chung-Han Ho, 5– 7 Mei-I Sung, 1 Shu-Chen Hsing, 1 Kuang-Ming Liao, 8 Shian-Chin Ko 1 1 Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan; 2 Department of Internal Medicine, Kaohsiung Veterans General Hospital Tainan Branch, Tainan, Taiwan; 3 Department of Internal Medicine, Cardinal Tien Hospital, New Taipei City, Taiwan; 4 Department of Internal Medicine, Chi Mei Medical Center, Liouying, Taiwan; 5 Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; 6 Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, 11695, Taiwan; 7 Department of Information Management, Southern Taiwan University of Science and Technology, Tainan, Taiwan; 8 Department of Internal Medicine, Chi Mei Medical Center, Chiali, Taiwan &astThese authors contributed equally to this work Correspondence: Kuang-Ming Liao, Department of Internal Medicine, Chi Mei Medical Center, Chiali, Taiwan, Email Shian-Chin Ko, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, Email Objective: To investigate the impact of a multidisciplinary intervention on the clinical outcomes of patients with COPD. Methods: This study retrospectively extracted the data of patients enrolled in the national pay-for-performance (P4P) program for COPD in four hospitals. Only COPD patients who received regular follow-up for at least one year in the P4P program between September 2018 and December 2020 were included. Results: A total of 1081 patients were included in this study. Among them, 424 (39.2%), 287 (26.5%), 179 (16.6%), and 191 (17.7%) patients were classified as COPD Groups A, B, C, and D, respectively. Dual therapy with long-acting β 2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) was the most used inhaled bronchodilator at baseline (n = 477, 44.1%) patients, followed by LAMA monotherapy (n = 195, 18.0%), triple therapy with inhaled corticosteroid (ICS)/LABA/LAMA (n = 184, 17.0%), and ICS/LABA combination (n = 165, 15.3%). After one year of intervention, 374 (34.6%) and 323 (29.9%) patients had their pre- and post-bronchodilator-forced expiratory volume in one second (FEV1) increase of more than 100 mL. Both the COPD Assessment Test (CAT) and modified British Medical Research Council (mMRC) scores had a mean change of − 2.2 ± 5.5 and − 0.3 ± 0.9, respectively. The improvement in pulmonary function and symptom score were observed across four groups. The decreased number of exacerbations was only observed in Groups C and D, and not in Groups A and B. Conclusion: This real-world study demonstrated that the intervention in the P4P program could help improve the clinical outcome of COPD patients. It also showed us a different view on the use of dual therapy, which has a lower cost in Taiwan. Keywords: chronic obstructive pulmonary disease, COPD, dual therapy, Disease-Specific Care – Chronic Obstructive Pulmonary Disease, DSC-COPD, certification program, Joint Commission of Taiwan, pay-for-performance, quality-improvement Chronic obstructive pulmonary disease (COPD) is a common airway disease characterized by persistent respiratory symptoms and airflow limitation. In contrast to other diseases, ie, cardiovascular disease, coronary artery disease, and stroke, which showed decreasing burden with time, the prevalence of COPD remains high and has been continuously a major health problem and an economic burden globally. 1,2 In 2015, 2.6% of the global disability-adjusted life year (DALY) was caused by COPD and 3.2 million people were estimated to die of COPD worldwide. 2 In Taiwan, there was no exception. The average annual prevalence of COPD in Taiwan, based on the National Health Insurance medical reimbursement claims from 1996 to 2002, was 2.48%, with a rate up to 8.83% in those older than 70 years of age. 3 A study of the impact of COPD in the Asia‐Pacific region—the Epidemiology and Impact of COPD (EPIC) Asia population‐based survey—used telephone or face‐to‐face interviews in 6,000 residents of the Asia‐Pacific and detected a prevalence rate of 9.5% in 207 Taiwanese patients. 4 In 2019, chronic lower respiratory disease ranked as the seventh cause of death in Taiwan, with a mortality rate of 26.7 per 100,000 population. Additionally, the in-hospital mortality rate for COPD patients requiring hospitalization remained 4% and the 1‐year mortality rate was as high as 22%. 3 To improve the clinical outcome of patients with COPD in Taiwan, the Bureau of National Heal -Abstract Truncated-